VAREX IMAGING (VREX) reported $212.9 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 3.3%. EPS of $0.26 for the same period compares to $0.16 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $206.83 million, representing a surprise of +2.93%. The company delivered an EPS surprise of +85.71%, with the consensus EPS estimate being $0.14.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how VAREX IMAGING performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Industrial: $59.10 million versus $59.12 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +3% change.
- Revenues- Medical: $153.80 million compared to the $147.36 million average estimate based on two analysts. The reported number represents a change of +3.4% year over year.
- Gross profit- Industrial: $20.80 million versus $19.64 million estimated by two analysts on average.
- Gross profit- Medical: $55.90 million versus the two-analyst average estimate of $48.61 million.
View all Key Company Metrics for VAREX IMAGING here>>>
Shares of VAREX IMAGING have returned -6% over the past month versus the Zacks S&P 500 composite's +11.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
VAREX IMAGING (VREX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
